Current research status of methylation quantification of FAM19A4 gene promoter in cervical cancer and its precancerous lesion screening

doi:10.3877/cma.j.issn.1673-5250.2021.01.004

Cervical cancer is one of the most common gynecologic malignancies. At present, human papillomavirus (HPV) and cytological test are the main screening methods for cervical cancer and its precancerous lesions (CCPL). As the above traditional screening methods have the risk of missed diagnosis of CCPL, it is of great significance to find specific molecular markers that can effectively identify CCPL. Methylation quantification of family with sequence similarity 19 member A4 (FAM19A4) gene promoter can effectively detect CCPL tissues, with higher specificity than traditional screening methods, and is expected to be a specific molecular marker for screening CCPL. The authors intend to describe methylation quantification of FAM19A4 gene promoter in CCPL screening in order to provide ideas for further promoting the development of CCPL screening methods.

Key words: Uterine cervical neoplasms, Precancerous conditions, Molecular targeted therapy, Molecular markers, DNA methylation, FAM19A4, Promoter regions, genetic, Female

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	王临虹，赵更力. 中国子宫颈癌综合防控指南[J]. 中国妇幼健康研究，2018, 29(1): 1-3. DOI: 10.3969/j.issn.1673-5293.2018.01.001.
[3]	Vink FJ, Lissenberg-Witte BI, Meijer CJLM, et al. FAM19A4/miR124-2 methylation analysis as a triage test for HPV-positive women: cross-sectional and longitudinal data from a Dutch screening cohort[J]. Clinc Microbiol Infect, 2020: S1198-743X(20)30163-4. DOI: 10.1016/j.cmi.2020.03.018.
[4]	Koliopoulos G, Nyaga VN, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population[J]. Cochrane Database Syst Rev, 2017, 8(8): CD008587. DOI: 10.1002/14651858.CD008587.pub2.
[5]	Bowden SJ, Lathouras K, Kyrgiou M. Can DNA methylation tests improve the accuracy of cervical screening？[J]. BJOG, 2021, 128(3): 515. DOI: 10.1111/1471-0528.16448.
[6]	布俏雯，张亮，王三锋，等. FAM19A4基因启动子甲基化检测在宫颈癌组织中的临床意义[J]. 实用医学杂志，2018, 34(9): 1541-1544, 1553. DOI: 10.3969/j.issn.1006-5725.2018.09.033.
[7]	De Strooper L, Berkhof J, Steenbergen R, et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4/ mir124-2 methylation test: a post hoc analysis in the POBASCAM trial with 14 year follow-up[J]. Int J Cancer, 2018, 143(6): 1541-1548. DOI: 10.1002/ijc.31539.
[8]	De Strooper LMA, Meijer CJ, Berkhof J, et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions[J]. Cancer Prev Res (Phila), 2014, 7(12): 1251-1257. DOI: 10.1158/1940-6207.CAPR-14-0237.
[9]	Bao H, Zhang L, Wang L, et al. Significant variations in the cervical cancer screening rate in China by individual-level and geographical measures of socioeconomic status: a multilevel model analysis of a nationally representative survey dataset[J]. Cancer Med, 2018, 7(5): 2089-2100. DOI: 10.1002/cam4.1321.
[10]	Cuschieri K, Ronco G, Lorincz A, et al. Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs[J]. Int J Cancer, 2018, 143(4): 735-745. DOI: 10.1002/ijc.31261.
[11]	霍文婧，梁茂盛，韩存芝. 人乳头瘤病毒联合薄层液基细胞检查在子宫颈疾病筛查中的应用[J]. 肿瘤研究与临床，2016, 28(2): 103-106. DOI: 10.3760/cma.j.issn.1006-9801.2016.02.008.
[12]	赵君，赵媛. 液基细胞学与HPV分型联合检测对早期宫颈癌的筛查意义[J]. 实用癌症杂志，2018, 33(1): 143-146. DOI: 10.3969/j.issn.1001-5930.2018.01.044.
[13]	Lorincz AT. Virtues and weaknesses of DNA methylation as a test for cervical cancer prevention[J]. Acta Cytol, 2016, 60(6): 501-512. DOI: 10.1159/000450595.
[14]	Luttmer R, De Strooper LM, Berkhof J, et al. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study)[J]. Int J Cancer, 2016, 138(4): 992-1002. DOI: 10.1002/ijc.29824.
[15]	Vink FJ, Meijer C, Clifford GM, et al. FAM19A4/ miR124-2 methylation in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Int J Cancer, 2019, 147(4): 1215-1221. DOI: 10.1002/ijc.32614.
[16]	Mac M, Moody CA. Epigenetic regulation of the human papillomavirus life cycle[J]. Pathogens, 2020, 9(6): 483. DOI: 10.3390/pathogens9060483.
[17]	Feng C, Dong J, Chang W, et al. The progress of methylation regulation in gene expression of cervical cancer[J]. Int J Genomics, 2018, 2018: 8260652. DOI: 10.1155/2018/8260652.
[18]	Kelly H, Benavente Y, Pavon MA, et al. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and Meta-analysis[J]. Br J Cancer, 2019, 121(11): 954-965. DOI: 10.1038/s41416-019-0593-4.
[19]	Au Yeung CL, Tsang WP, Tsang TY, et al. HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53[J]. Oncol Rep, 2010, 24(6): 1599-1604. DOI: 10.3892/or_00001023.
[20]	Zhang J, Yang C, Wu C, et al. DNA methyltransferases in cancer: biology, paradox, aberrations, and targeted therapy[J]. Cancers (Basel), 2020，12(8): 2123. DOI: 10.3390/cancers12082123.
[21]	Steenbergen RD, Ongenaert M, Snellenberg S, et al. Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis[J]. J Pathol, 2013, 231(1): 53-62. DOI: 10.1002/path.4210.
[22]	Bu Q, Wang S, Ma J, et al. The clinical significance of FAM19A4 methylation in high-risk HPV-positive cervical samples for the detection of cervical (pre)cancer in Chinese women[J]. BMC Cancer, 2018, 18(1): 1182. DOI: 10.1186/s12885-018-4877-5.
[23]	Jee B, Yadav R, Pankaj S, et al. Immunology of HPV-mediated cervical cancer: current understanding[J]. Int Rev Immunol, 2020: 1-20. DOI: 10.1080/08830185.2020.1811859.
[24]	Luttmer R, De Strooper LM, Steenbergen RD, et al. Management of high-risk HPV-positive women for detection of cervical (pre)cancer[J]. Expert Rev Mol Diagn, 2016, 16(9): 961-974. DOI: 10.1080/14737159.2016.1217157.
[25]	Tom TY, Emtage P, Funk WD, et al. TAFA: a novel secreted family with conserved cysteine residues and restricted expression in the brain[J]. Genomics, 2004, 83(4): 727-734. DOI: 10.1016/j.ygeno.2003.10.006.
[26]	Delfini M, Mantilleri A, Gaillard S, et al. TAFA4, a chemokine-like protein, modulates injury-induced mechanical and chemical pain hypersensitivity in mice[J]. Cell Rep, 2013, 5(2): 378-388. DOI: 10.1016/j.celrep.2013.09.013.
[27]	Wang W, Li T, Wang X, et al. FAM19A4 is a novel cytokine ligand of formyl peptide receptor 1 (FPR1) and is able to promote the migration and phagocytosis of macrophages[J]. Cell Mol Immunol, 2015, 12(5): 615-624. DOI: 10.1038/cmi.2014.61.
[28]	Shi X, Doycheva DM, Xu L, et al. Sestrin2 induced by hypoxia inducible factor1 alpha protects the blood-brain barrier via inhibiting VEGF after severe hypoxic-ischemic injury in neonatal rats[J]. Neurobiol Dis, 2016, 95: 111-121. DOI: 10.1016/j.nbd.2016.07.016.
[29]	Vink MA, Bogaards JA, van Kemenade FJ, et al. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data[J]. Am J Epidemiol, 2013, 178(7): 1161-1169. DOI: 10.1093/aje/kwt077.
[30]	Polman NJ, Snijders P, Kenter GG, et al. HPV-based cervical screening: rationale, expectations and future perspectives of the new Dutch screening programme[J]. Prev Med, 2019, 119: 108-117. DOI: 10.1016/j.ypmed.2018.12.021.
[31]	Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive[J]. J Low Genit Tract Dis, 2013, 17(5 Suppl 1): S56-S63. DOI: 10.1097/LGT.0b013e318285437b.
[32]	Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and Meta-analysis[J]. BJOG, 2011, 118(9): 1031-1041. DOI: 10.1111/j.1471-0528.2011.02944.x.
[33]	Kremer WW, Berkhof J, Bleeker MC, et al. Role of FAM19A4/miR124-2 methylation analysis in predicting regression or nonregression of CIN2/3 lesions: a protocol of an observational longitudinal cohort study[J]. BMJ Open, 2019, 9(7): e29017. DOI: 10.1136/bmjopen-2019-029017.
[34]	De Strooper LMA, Verhoef VMJ, Berkhof J, et al. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage-and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women[J]. Gynecol Oncol, 2016, 141(2): 341-347. DOI: 10.1016/j.ygyno.2016.02.012.
[35]	Hesselink AT, Heideman DAM, Steenbergen RDM, et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy[J]. Int J Cancer, 2014, 135(4): 880-886. DOI: 10.1002/ijc.28723.
[36]	Steenbergen RDM, Snijders PJF, Heideman DAM, et al. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions[J]. Nat Rev Cancer, 2014, 14(6): 395-405. DOI: 10.1038/nrc3728.
[37]	Tainio K, Athanasiou A, Tikkinen K, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and Meta-analysis[J]. BMJ, 2018, 360: k499. DOI: 10.1136/bmj.k499.
[38]	伍恒英，彭苏珺，布俏雯，等. FAM19A4基因启动子甲基化在高危型HPV阴性宫颈癌诊断中的作用[J]. 实用医学杂志，2019, 35(5): 683-687. DOI: 10.3969/j.issn.1006-5725.2019.05.002.
[39]	Kurokawa T, Yoshida Y, Iwanari O, et al. Implementation of primary HPV testing in Japan[J]. Mol Clin Oncol, 2020, 13(4): 22. DOI: 10.3892/mco.2020.2092.

[1]	Shuqin Zhang, Lian Chen. Diagnosis and treatment of postpartum intrauterine retained products of conception[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 493-497.
[2]	Qin Liu, Hanmin Liu, Liang Xie. Current status of research on the role of matrix metalloproteinases in the pathogenesis of childhood asthma[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 564-568.
[3]	Jiechun Shi, Ziyu Fan, Yan Xing. Early warning efficiency of different screening methods on cervical adenocarcinoma in situ[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 575-581.
[4]	Dan Tang, Xiaoxi Yao, Bowen Yang, Shaolong Xue, Mengyao Li, Liuxing Wei, Mingrong Xi. The impact of doublecortin-like kinase 1 on the clinical characteristics of endometrioid adenocarcinoma patients[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 582-590.
[5]	Yi Wei, Yuxi Zhou, Ye Yang, Xiufeng Ling, Chun Zhao. Current research status on roles of microRNA on endometrial receptivity[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(03): 266-270.
[6]	Lin Lin, Simeng Tian, Yonghua Yu, Feifei Xu, Mingli Huang. Current research status on treatment of intrauterine adhesion by stem cells and their exosomes[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(03): 271-275.
[7]	Xin Li, Yi Wei, Juan Zhang, Juanjuan Zhang, Xiufeng Ling, Chun Zhao, Mianqiu Zhang. Influencing factors on clinical pregnancy outcomes of frozen-thaw embryo transfer cycle in women of advanced age[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(03): 276-283.
[8]	Weicong Gao, Li Li, Zhonghua Zhang, Xianghui Zhu, Suqiao Liu. Impact of impaired glucose regulation on recurrence within 2 years after modified radical surgery in patients with cervical cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 231-237.
[9]	Yuping Li, Hui Ma, Hang Yu. Clinical efficacy of laparoscopic uterine artery ligation combined with myomectomy for the treatment of uterine fibroids[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 238-244.
[10]	Lin Yang, Rutie Yin. Current research status on etiology and treatment of patients with white lesions of vulva[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 157-165.
[11]	Qing Liu, Zhiling Wang. Gut mycobiome and pediatric inflammatory bowel disease[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 172-178.
[12]	Li Wang, Yueying Wang, Fen Zhou, Yukun Guo, Lina Wei. Current research status in effect of gonadotropin-releasing hormone antagonist on endometrial receptivity[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(06): 629-635.
[13]	Xiaoyong Wei. Discussion on the focus issues of conversion therapy for primary liver cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 602-607.
[14]	Xuejing Chen, Lijuan Zhou, Hong Zhao, Li Zhang, Zuyu Sun, Nanying Che. Value of DNA methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid combined with cytopathologic detection in diagnosis of lung cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 139-143.
[15]	Pu Li, Xiujie Sheng. Management of pregnancy complicated with cervical cancer[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2024, 13(04): 202-208.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export